Inhibitory effect of doxycycline against dengue virus replication in vitro

Archives of Virology

Volumn 159, Issue 4, 2014, Pages 711-718

  Rothan, Hussin A ^a   Mohamed, Zulqarnain ^a   Paydar, Mohammadjavad ^a   Rahman, Noorsaadah Abd ^a   Yusof, Rohana ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DOXYCYCLINE; NS2B PROTEIN, FLAVIVIRUS; VIRUS PROTEIN;

ARTICLE; DENGUE VIRUS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IC 50; PHYSIOLOGY; VIRUS CULTURE; VIRUS ENTRY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DENGUE VIRUS; DOXYCYCLINE; HUMANS; INHIBITORY CONCENTRATION 50; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PLAQUE ASSAY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84897034680     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1880-7     Document Type: Article

References (37)

1. Brinton MA (2002) The molecular biology of West Nile virus: a new invader of the Western hemisphere. Annu Rev Microbiol 56: 371-402.
2. Hayes EB, Gubler DJ (2006) West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57: 181-194.
3. Botting C, Kuhn RJ (2012) Novel approaches to flavivirus drug discovery. Expert Opin Drug Discov 7: 417-428.
4. Monath TP (1994) Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 91: 2395-2400.
5. Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1: 55-57.
6. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100-103.
7. Muhammad Azami NA, Salleh SA, Neoh HM, Syed Zakaria SZ, Jamal R (2011) Dengue epidemic in Malaysia: not a predominantly urban disease anymore. BMC Res Notes 4: 216.
8. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100: 6986-6991.
9. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427: 313-319.
10. Tomlinson SM, Malmstrom RD, Watowich SJ (2009) New approaches to structure-based discovery of dengue protease inhibitors. Infect Disord Drug Targets 9: 327-343.
11. Orellana MA, Gomez-Lus ML (2011) Which is the best empirical treatment in patients with urethritis? Rev Esp Quimioter 24: 136-142.
12. Polat KY, Tosun MS, Ertekin V, Aydinli B, Emre S (2012) Brucella infection with pancytopenia after pediatric liver transplantation. Transpl Infect Dis 14: 326-329.
13. Skulason S, Holbrook WP, Thormar H, Gunnarsson GB, Kristmundsdottir T (2012) A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. J Oral Pathol Med 41: 61-67.
14. James R, Wilcox RN et al (2012) Doxycycline as a modulator of inflammation in chronic wounds. Wounds 24: 339-349.
15. Buckingham SC (2005) Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies. Paediatr Drugs 7: 163-176.
16. Kirchner JT, Emmert DH (2000) Sexually transmitted diseases in women. Chlamydia trachomatis and herpes simplex infections. Postgrad Med 107(55-58): 55-61.
17. Sturtz FG (1998) Antimurine retroviral effect of doxycycline. Methods Find Exp Clin Pharmacol 20: 643-647.
18. Yang JM, Chen YF, Tu YY, Yen KR, Yang YL (2007) Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS One 2: e428.
19. Manning MW, Cassis LA, Daugherty A (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 23: 483-488.
20. Rothan HA, Abdulrahman AY, Sasikumer PG, Othman S, Rahman NA et al (2012) Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J Biomed Biotechnol 2012: 251482.
21. Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA et al (2012) Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis 12: 314.
22. Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R (2000) Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 275: 9963-9969.
23. Yon C, Teramoto T, Mueller N, Phelan J, Ganesh VK et al (2005) Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. J Biol Chem 280: 27412-27419.
24. Lin C, Amberg SM, Chambers TJ, Rice CM (1993) Cleavage at the novel site in the NS4A region by the yellow fever virus NS2B-3proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J Virol 67: 2327-2335.
25. Arias CF, Preugschat F, Strauss JH (1993) Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 193: 888-899.
26. Lobigs M (1993) Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc Natl Acad Sci USA 90: 6218-6222.
27. Clum S, Ebner KE, Padmanabhan R (1997) Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3 (Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B. J Biol Chem 272: 30715-30723.
28. Teo KF, Wright PJ (1998) Internal proteolysis of the NS3 protein specified by dengue virus 2. J Gen Microbiol 78: 337-341.
29. Stocks CE, Lobigs M (1998) Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J Virol 72: 2141-2149.
30. Geiss BJ, Stahla H, Hannah AM, Gari AM, Keenan SM (2009) Focus on flaviviruses: current and future drug targets Future. Med Chem 1: 327-344.
31. Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim S et al (2006) Structural basis for the activation of flaviviralNS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13: 372-373.
32. Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A (2011) Novel dengue virus-specific NS2B/NS3 Protease Inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother 55: 229-238.
33. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL et al (1995) The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 36: 418-424.
34. Dong M, Zhong L, Chen WQ, Ji XP, Zhang M et al (2012) Doxycycline stabilizes vulnerable plaque via inhibiting matrix metalloproteinases and attenuating inflammation in rabbits. PLoS ONE 7(6): e39695.
35. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I et al (1999) Dengue virus structural differences that correlate with pathogenesis. J Virol 73: 4738-4747.
36. Halsey ES, Marks MA, Gotuzzo E, Fiestas V, Suarez L et al (2012) Correlation of serotype-specific dengue virus infection with clinical manifestations. PLoS Negl Trop Dis 6: e1638.
37. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI et al (2006) Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74: 449-456.